XML 19 R8.htm IDEA: XBRL DOCUMENT
v3.22.0.1

LOSS PER SHARE AND STOCKHOLDERS’ EQUITY: | 9 Months Ended
--- | ---
Dec. 31, 2021
EARNINGS (LOSS) PER SHARE AND STOCKHOLDERS' EQUITY: |
LOSS PER SHARE AND STOCKHOLDERS’ EQUITY: | LOSS PER SHARE AND STOCKHOLDERS’ EQUITY: Loss Per Share A reconciliation of the numerator and denominator of basic and diluted loss per share is shown below (in thousands, except per share amounts):
|  | For the three months ended |  | For the nine months ended
|  | December 31, |  | December 31,
|  | 2021 |  | 2020 |  | 2021 |  | 2020
Basic loss per share: |  |  |  |  |  |  |  |
Net loss |  | $ | (15,375) |  |  | $ | (11,725) |  |  | $ | (4,441) |  |  | $ | (57,421) |
Basic weighted-average shares outstanding |  | 68,190 |  |  | 66,523 |  |  | 68,187 |  |  | 66,034 |
Basic loss per share |  | $ | (0.23) |  |  | $ | (0.18) |  |  | $ | (0.07) |  |  | $ | (0.87) |
Diluted loss per share: |  |  |  |  |  |  |  |
Basic weighted-average shares outstanding |  | 68,190 |  |  | 66,523 |  |  | 68,187 |  |  | 66,034 |
Dilutive effect of common stock options and restricted stock as computed under the treasury stock method (1) |  | — |  |  | — |  |  | — |  |  | — |
Diluted weighted-average shares outstanding |  | 68,190 |  |  | 66,523 |  |  | 68,187 |  |  | 66,034 |
Diluted loss per share |  | $ | (0.23) |  |  | $ | (0.18) |  |  | $ | (0.07) |  |  | $ | (0.87) |
(1) The number of common stock options and restricted stock units as computed under the treasury stock method that would have otherwise been dilutive but are excluded from the table above because their effect would have been anti-dilutive due to the net loss position of the Company was (i) 1.7 million and 1.4 million in the three and nine months ended December 31, 2021, respectively and (ii) 3.3 million and 2.6 million in the three and nine months ended December 31, 2020, respectively. Restricted stock units that were outstanding during the periods presented but were not included in the computation of diluted loss per share because their effect would have been anti-dilutive (other than due to the net loss position of the Company) are shown below (shares in thousands):
|  | For the three months ended |  | For the nine months ended
|  | December 31, |  | December 31,
|  | 2021 |  | 2020 |  | 2021 |  | 2020
Number of shares underlying restricted stock units |  | 484 |  |  | — |  |  | 787 |  |  | 141 |
Stockholders’ Equity Under the modified common stock repurchase program, the Company may purchase up to $1.0 billion of its common stock through the period ending December 31, 2022. During the nine months ended December 31, 2021, the Company repurchased 1.1 million shares of its common stock for $49.2 million under the stock repurchase program. Through December 31, 2021, the Company had repurchased a total of 29.4 million shares of its stock for $722.8 million under the stock repurchase program, leaving remaining capacity of $277.2 million. Accumulated other comprehensive income balances of $5.9 million and $7.5 million at December 31, 2021 and March 31, 2021, respectively, reflect accumulated foreign currency translation adjustments.

X
- References No definition available. + Details
Name: | ramp_EarningsPerShareAndStockholdersEquityDisclosureAbstract
Namespace Prefix: | ramp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ramp_EarningsPerShareAndStockholdersEquityDisclosureTextBlock
Namespace Prefix: | ramp_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration